Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuCellICCC +4.00%54 FCF Yield % is 4.58 as of Aug. 20, 2026. GuruFocus rates ICCC with a GF Score™ of 54/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, ImmuCell ranks better than 93.62% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
ImmuCell FCF Yield % Related Terms
ImmuCell FCF Yield % Historical Data
* Premium members only.
The historical data trend for ImmuCell's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ImmuCell's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuCell FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuCell's FCF Yield % distribution charts can be found below:
* The bar in red indicates where ImmuCell's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuCell (ICCC) has a FCF Yield % of 4.58 as of Aug. 20, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ImmuCell and its competitors. According to the industry distribution chart, ImmuCell ranks #90 out of 1410 companies in the Biotechnology industry, placing it in the top 6.4%.
Is ImmuCell's FCF Yield % too high?
ImmuCell's current FCF Yield % is 4.58. Based on the distribution chart, ImmuCell ranks #90 out of 1410 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, ImmuCell has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's FCF Yield % compare to COYA and ENTX?
According to the Biotechnology industry distribution chart, ImmuCell ranks #90 out of 1410 companies for FCF Yield %. This places ImmuCell in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ImmuCell and its competitors. ImmuCell's current FCF Yield % is 4.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.13 — trading 46.6% above its estimated fair value. The current FCF Yield % is 4.58. ImmuCell's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For ImmuCell (ICCC), the current FCF Yield % is 4.58 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ImmuCell (ICCC) Overvalued in 2026?
Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued.
The current stock price of $10.13 is trading 46.6% above its estimated GF Value™ of $6.91.
GuruFocus considers ImmuCell to be Significantly Overvalued.
Key valuation signals for ICCC:
FCF Yield %: 4.58
GF Value™: $6.91 vs. price of $10.13 (46.6% above fair value)
No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
54GF Score
Get the complete analysis for ICCC
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICCC has been successfully added to your 
